abstract |
Compositions for use as a vaccine against SARS-CoV-2 infection are disclosed, which comprise either a polypeptide that comprises at least one surge-associated mutation (e.g., deletion) in its amino acid sequence or a nucleic acid (e.g., mRNA) that encodes said polypeptide. Also disclosed are formulations that include these compositions, antibodies or their antigen-biding fragments directed to these polypeptides, methods of making such antibodies, methods of vaccinating subjects against SARS-CoV-2 infection, and methods of selecting an antibody, convalescent plasma, or vaccine against SARS-CoV-2 infection. |